BIO Top Priority Is Medicare Reimbursement Negotiations, Chairman Says
Executive Summary
Negotiating appropriate Medicare reimbursement rates is one of the Biotechnology Industry Organization's top priorities over the next two years, Alkermes CEO and BIO Chairman Richard Pops said Feb. 25
You may also be interested in...
Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling
Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness
Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling
Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness
Crawford Will Lead A Reorganized FDA As McClellan Leaves For CMS
FDA is likely entering another extended period with Deputy Commissioner Lester Crawford, PhD, at the helm following Commissioner McClellan's move to the Centers for Medicare & Medicaid Services